News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Spiracur Announces New SNaP SecurRing Hydrocolloid


3/7/2013 9:59:36 AM

SUNNYVALE, CA--(Marketwire - March 06, 2013) - Spiracur Inc., developer of the SNaP® Wound Care System, an advanced wound care dressing with the proven efficacy of Negative Pressure Wound Therapy (NPWT), announced today the introduction of its SNaP SecurRing™ Hydrocolloid. This new product, a hydrocolloid shaped into a ring, is designed to facilitate fast and easy applications of the SNaP Wound Care System on uneven skin surfaces or wounds in challenging locations. The new Hydrocolloid is intended for patients suffering from chronic wounds such as diabetic foot ulcers (DFU) or wounds to the plantar surface of the foot, as well as acute wounds, such as ray (toe) amputations.

"The SecurRing Hydrocolloid is an ideal solution for our clinic because it makes dressing applications faster and easier on a large number of our patients suffering from DFUs, ray amputations and plantar wounds," said Gary Rothenberg, DPM, CDE, CWS, director of Residency Training and Attending Podiatrist at the Miami Veterans Affairs Healthcare System in Miami, Fla. "When using the SecurRing Hydrocolloid, fewer accessories are required and less time is needed to get a seal. In addition, by using it with the SNaP Dressing, we can now apply NPWT in challenging anatomic locations, which would not have been previously considered," continued Dr. Rothenberg.

Dr. Rothenberg will present a poster entitled "Advances for Negative Pressure Wound Therapy in Challenging Anatomic Locations," at the Symposium for Advanced Wound Care (SAWC) Spring Conference in Denver, Colo., May 1-5, 2013. The poster describes the utilization of NPWT on an anatomically challenging location that otherwise would have been difficult to seal without the SecurRing Hydrocolloid. The SAWC meeting is the premier interdisciplinary wound care program and the largest annual gathering of wound care clinicians in the United States.

Spiracur's SecurRing Hydrocolloid is a sterile, moldable and absorptive wound care product formulated specifically to be compatible with the SNaP Wound Care Dressing. It is designed to fill uneven skin surfaces and mold around wounds in challenging anatomical locations. It protects the periwound tissue from maceration and increases adhesion of the hydrocolloid dressing. The end result is a sterile wound care product that will decrease application time and cost by reducing the need for adjunct products necessary to protect the wound from excess moisture and leaks.

The company is credited with creating a new category of chronic and acute wound management solutions by combining the benefits of advanced wound care with the proven efficacy of NPWT. The SNaP System is a mechanically powered, ultraportable NPWT system encompassing proprietary spring technology and gentle hydrocolloid dressing to maintain constant pressure. There is no electrical pump, the device is small and light, weighing only 2.2 ounces, and it is completely disposable.

"We are thrilled to provide the new SecurRing Hydrocolloid as the latest offering in our suite of wound care treatment solutions," said Dane Schackleford, vice president of sales for Spiracur Inc. "Patients who suffer chronic and acute wounds deserve options that provide fast and effective wound care treatment, while preserving dignity and mobility. Our new SecurRing Hydrocolloid coupled with our SNaP System provides a comprehensive solution to help this patient population and the clinicians who treat them."

About Spiracur Inc.
Spiracur Inc., headquartered in Sunnyvale, Calif., is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford University Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System for the treatment of chronic and acute wounds, is the result of patient and clinician feedback that current negative pressure wound therapies were too cumbersome. The company's ciSNaP® Closed Incision System with proprietary controlled tension relief is designed to improve healing of high-risk surgical incisions. Both devices have been cleared by the U.S. Food & Drug Administration (FDA) and have received CE Mark approval. For more information, please visit http://spiracur.com.

Spiracur, Spiracur logo, SNaP and SNaP & Design are registered trademarks of Spiracur Inc. SecurRing is a trademark of Spiracur Inc.


Media Contact:
Amy Cook
925.552.7893
Email Contact

Investor Contact:
Steve Van Dick
408.701.5300
Email Contact


Read at BioSpace.com

comments powered by Disqus
Spiracur
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES